United Therapeutics Corporation (UTHR) - Total Liabilities
Based on the latest financial reports, United Therapeutics Corporation (UTHR) has total liabilities worth $760.90 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
United Therapeutics Corporation - Total Liabilities Trend (1998–2024)
This chart illustrates how United Therapeutics Corporation's total liabilities have evolved over time, based on quarterly financial data. See UTHR current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
United Therapeutics Corporation Competitors by Total Liabilities
The table below lists competitors of United Therapeutics Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Telenor ASA
OL:TEL
|
Norway | Nkr154.76 Billion |
|
AXIA Energia SA
NYSE:AXIA-PC
|
USA | $158.72 Billion |
|
Church & Dwight Company Inc
NYSE:CHD
|
USA | $4.82 Billion |
|
Telefonica SA ADR
NYSE:TEF
|
USA | $71.22 Billion |
|
Guangdong Songfa Ceramics Co
SHG:603268
|
China | CN¥46.43 Billion |
|
Coca-Cola Femsa SAB de CV ADR
NYSE:KOF
|
USA | $166.52 Billion |
|
Tenaga Nasional Bhd
KLSE:5347
|
Malaysia | RM145.38 Billion |
|
Vinhomes JSC
VN:VHM
|
Vietnam | ₫538.47 Trillion |
Liability Composition Analysis (1998–2024)
This chart breaks down United Therapeutics Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of United Therapeutics Corporation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how United Therapeutics Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for United Therapeutics Corporation (1998–2024)
The table below shows the annual total liabilities of United Therapeutics Corporation from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $920.00 Million | -22.18% |
| 2023-12-31 | $1.18 Billion | -5.26% |
| 2022-12-31 | $1.25 Billion | +3.11% |
| 2021-12-31 | $1.21 Billion | -0.79% |
| 2020-12-31 | $1.22 Billion | +7.66% |
| 2019-12-31 | $1.13 Billion | +85.01% |
| 2018-12-31 | $612.40 Million | -21.24% |
| 2017-12-31 | $777.60 Million | +67.80% |
| 2016-12-31 | $463.40 Million | -20.76% |
| 2015-12-31 | $584.80 Million | -5.50% |
| 2014-12-31 | $618.84 Million | -20.99% |
| 2013-12-31 | $783.26 Million | +47.30% |
| 2012-12-31 | $531.73 Million | -6.65% |
| 2011-12-31 | $569.59 Million | +3.99% |
| 2010-12-31 | $547.75 Million | +37.44% |
| 2009-12-31 | $398.54 Million | +9.60% |
| 2008-12-31 | $363.62 Million | +24.86% |
| 2007-12-31 | $291.23 Million | +6.31% |
| 2006-12-31 | $273.94 Million | +1579.50% |
| 2005-12-31 | $16.31 Million | +5.08% |
| 2004-12-31 | $15.52 Million | +32.25% |
| 2003-12-31 | $11.74 Million | -9.07% |
| 2002-12-31 | $12.91 Million | -17.90% |
| 2001-12-31 | $15.72 Million | -1.16% |
| 2000-12-31 | $15.91 Million | +152.50% |
| 1999-12-31 | $6.30 Million | +215.00% |
| 1998-12-31 | $2.00 Million | -- |
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer;… Read more